Patents by Inventor Taoshan JIANG

Taoshan JIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EGFR and ALK dual inhibitor
    Patent number: 10350210
    Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 16, 2019
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Jing Liu, Qingsong Liu, Taoshan Jiang, Aoli Wang, Jiaxin Wu, Hong Wu, Ziping Qi, Yongfei Chen, Fengming Zou, Wenchao Wang, Zheng Zhao, Li Wang, Beilei Wang
  • NOVEL EGFR AND ALK DUAL INHIBITOR
    Publication number: 20180369242
    Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 27, 2018
    Applicant: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Jing LIU, Qingsong LIU, Taoshan JIANG, Aoli WANG, Jiaxin WU, Hong WU, Ziping QI, Yongfei CHEN, Fengming ZOU, Wenchao WANG, Zheng ZHAO, Li WANG, Beilei WANG